Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.36 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129790 | 0.85 | ALDH1A1 (0.46) | MEN1KMT2ACA2CA4IDO1 | |
| SCHEMBL286889 | 0.85 | MEN1 (0.41) | MEN1KMT2ACA2IDO1ALDH1A1 | |
| SCHEMBL11145069 | 0.82 | MEN1 (0.40) | MEN1KMT2ACA2IDO1ALDH1A1 | |
| SCHEMBL23536830 | 0.82 | GABRA1 (0.52) | MEN1KMT2AIDO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL1364220 | 0.82 | MEN1 (0.41) | MEN1KMT2ACA2CA4IDO1 | |
| SCHEMBL31172578 | 0.82 | CA2 (0.41) | MEN1KMT2ACA2CA4ALDH1A1 | |
| SCHEMBL30525679 | 0.82 | MEN1 (0.41) | MEN1KMT2ACA2CA4IDO1 | |
| SCHEMBL16953890 | 0.81 | GABRA1 (0.38) | MEN1KMT2AIDO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL560920 | 0.80 | IDO1 (0.42) | MEN1KMT2AIDO1ALDH1A1MAPT | |
| SCHEMBL129805 | 0.80 | ALDH1A1 (0.38) | MEN1KMT2ACA2CA4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114181144-B | Fluorobiphenyl methyl resorcinol ether derivative, preparation method and application thereof | 浙江工业大学 | 2023-04-04 | — | — | CN | disclosed |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. | 2023-03-02 | — | — | US | disclosed |
| CN-108368090-B | Compounds as immunomodulators | 百时美施贵宝公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114181144-A | Fluorobiphenyl methyl resorcinol ether derivative, preparation method and application thereof | 浙江工业大学 | 2022-03-15 | — | — | CN | disclosed |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2020-10-22 | — | — | US | disclosed |
| US-10745382-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-18 | — | — | US | disclosed |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-06-11 | — | — | US | disclosed |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN INC (US) | 2018-12-06 | — | — | US | disclosed |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2018-08-30 | — | — | US | disclosed |
| EP-3362443-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2018-08-22 | — | — | EP | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ALLERGAN, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ALLERGHAN, INC. | 2008-08-14 | — | — | US | disclosed |
| US-6476021-B1 | Compounds having cGMP-PDE inhibitory effect | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-1048666-A1 | NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2000-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306161-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | MEN1 3787/4885KMT2A 3926/4885CA2 1162/4885 |
| US-10316035-B2 | Triazolopyridine inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | MEN1 4533/4885KMT2A 1655/4885CA2 1240/4885 |
| US-20230062049-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | MEN1 3477/4885KMT2A 3972/4885CA2 1491/4885 |
| US-20180244671-A1 | TRIAZOLOPYRIDINE INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | MEN1 4533/4885KMT2A 1655/4885CA2 1240/4885 |
| US-20090306398-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2C, ADRA2A | MEN1 3787/4885KMT2A 3926/4885CA2 1162/4885 |
| US-10745382-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | MEN1 1857/4885KMT2A 4121/4885CA2 4677/4885 |
| US-20200330428-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | MEN1 3477/4885KMT2A 3972/4885CA2 1491/4885 |
| US-20080194650-A1 | ARYL FLUOROETHYL UREAS ACTING AS ALPHA 2 ADRENERGIC AGENTS | ADRB2, ADRA2C, ADRA2A | MEN1 3899/4885KMT2A 1150/4885CA2 4291/4885 |
| US-20180344692-A1 | METHODS OF TREATING ALPHA ADRENERGIC MEDIATED CONDITIONS | ADRB2, ADRA2A, ADRA2C | MEN1 3477/4885KMT2A 3972/4885CA2 1491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.